HARBIN, China, Aug. 4, 2011 /PRNewswire-Asia/ -- China Botanic Pharmaceutical Inc. (NYSE AMEX: CBP) ("China Botanic" or the "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ("TCM") in China, today announced that the Company successfully showcased its all-natural products at the 46th National Special Drugs Commodities Fair (the "Drug Fair") held in Nanjing International Expo Center in July 2011.
China Botanic's new product candidates such as Lyophilized Syringin Powder and Total Flavonoids Capsules showcased at the Drug Fair attracted significant attention from merchants and distributors. These products are currently undergoing pharmacological tests and clinical tests prior to their release. The Company utilizes its proprietary technique for extracting effective parts of Siberian Ginseng to produce Lyophilized Syringin Powder and Total Flavonoids Capsules, which are powerful new tools in combating depression and senile dementia. These new products have been recognized as "class one new drugs" and "innovative drugs" by the State Food and Drug Administration of China.
"We are a certified national high tech enterprise, and the drug fair provides us an excellent platform to showcase our innovative products and remedies. The wave of all-natural bio-pharmaceutical products has changed the consumer's perception of the treatment of depression and other disorders," said Mr. Shaoming Li, Chairman and Chief Executive Officer of China Botanic. "We are very pleased to have seen growing market recognition for our product offerings at similar drug fairs or exhibitions and will continue to reach out to our target audience to strengthen understanding of our products and their benefits."
ABOUT CHINA NATIONAL NEW AND SPECIAL DRUG FAIR (THE "DRUG FAIR")
The drug fair is a most influential event in the Chinese pharmaceutical industry. It is a showcase for new and special drugs, the exchange of services, and focuses on the entire lifecycle of a new drug, from development to commercialization. One of the most prestigious drug conventions in China, the drug fair has an over 30 year history. The 46th drug fair featured 1400 exhibition booths, with over 1000 pharmaceutical companies attending.
ABOUT CHINA BOTANIC PHARMACEUTICAL INC.
China Botanic Pharmaceutical Inc. is engaged in the research, development, manufacturing, and distribution of botanical products, bio-pharmaceutical products, and traditional Chinese medicines ("TCM"), in the People's Republic of China. All of the Company's products are produced at its three GMP-certified production facilities in Ah City, Dongfanghong and Qingyang. The Company distributes its botanical anti-depression and nerve-regulation products, biopharmaceutical products, and botanical antibiotic and OTC TCMs through its network of over 3,000 distributors and over 70 sales centers across 24 provinces in China. For more information, please visit www.renhuang.com.
Safe Harbor Statement
This press release contains certain statements that may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based upon management's beliefs, assumptions and expectations of the Company's future operations and financial performance, taking into account the information currently available to management. These statements are not statements of historical fact. Forward-looking statements involve risks and uncertainties, some of which are not currently known that may cause actual results, performance or financial condition to be materially different from the expectations of future results, performance or financial condition expressed or implied in any forward-looking statements. These forward-looking statements are based on current plans and expectations and are subject to a number of uncertainties including, but not limited to, the Company's ability to manage expansion of its operations effectively, and other factors detailed in the Company's annual report on Form 10-K and other filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented herein.
CCG Investor Relations:
China Botanic Pharmaceutical Inc.
Mr. Mark Collinson, Partner
Ms. Portia Tan, IR Contact
Phone: +1-310-954-1343 (Los Angeles)
Mr. Crocker Coulson, President
Phone: +1-646-213-1915 (New York)
SOURCE China Botanic Pharmaceutical Inc.